# OnCo record quanta-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/quanta-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "quanta-therapeutics" ;
  schema:name "Quanta Therapeutics"@en ;
  schema:description "Quanta Therapeutics develops oral multi-KRAS inhibitors biased to G12D (QTX3034) and G12V (QTX3544), with responses in pancreatic, colorectal, and endometrial cancer."@en ;
  schema:url <https://onco.cc/companies/quanta-therapeutics/>, <https://www.quantatx.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.quantatx.com/news/030526/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/endometrial/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> .